Detailed price information for Royalty Pharma Plc Cl A (RPRX-Q) from The Globe and Mail including charting and trades.

Even though oncology segment revenue inched up just 1 percent year over year, the firm lifted full-year expectations slightly ...

Gilead stock briefly broke out Friday after the biotech company beat second-quarter forecasts amid its newest launch in HIV ...

Gilead Sciences ( NASDAQ: GILD) was upgraded to Buy from Hold at Truist after the company raised full year sales and profit ...

Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed ...

Shares in Gilead Sciences were a massive 9% higher in Friday’s early trading after the US biotech major lifted its full-year financial guidance.

Adjusted earnings per share (EPS) of $2.01 beat the Zacks Consensus Estimate of $1.95 and remained flat year over year.

Gilead Sciences generates stellar profit margins with its HIV and hepatitis C virus, or HCV, portfolio, which requires only a small salesforce and inexpensive manufacturing. We think its portfolio and ...

Gilead Sciences, Inc.'s HIV dominance with Biktarvy & Yeztugo boosts revenue potential. Click for more about GILD and its ...

While the top- and bottom-line numbers for Gilead (GILD) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to ...

(Nasdaq: GILD) announced today its second quarter 2025 results of operations. "This was a very successful second quarter for Gilead, including the FDA approval for Yeztugo as the world’s first ...

Gilead Sciences on Thursday reported flat second-quarter earnings on slightly higher revenue and raised its full-year ...